Navigation Links
Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer
Date:5/15/2008

Phase II Data Presented at ASCO Showed Acceptable Tolerability Profile,

with Low Incidence of Grade 3 and 4 Neuropathy

WOODCLIFF LAKE, N.J., May 15 /PRNewswire/ -- The investigational chemotherapeutic agent eribulin mesylate (E7389) demonstrated activity in a heavily pretreated population of women with locally advanced or metastatic breast cancer, according to results of a multi-center Phase II clinical trial. The study also suggests that eribulin mesylate has a manageable tolerability profile, with a low incidence of Grade 3 (severe) and no Grade 4 (disabling or life-threatening) neuropathy. These data (abstract #1084) will be presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) on Monday, June 2 from 2 to 6 p.m. at S Hall A1 of McCormick Place.

"The anti-tumor activity of eribulin mesylate, as observed in this study, is encouraging, given the limited treatment options for women with advanced breast cancer who have previously received multiple lines of therapy," said lead investigator Linda T. Vahdat, MD, of Weill Cornell Medical College in New York. "The subjects in this trial had received a median of four prior chemotherapy regimens that included an anthracycline, a taxane and capecitabine."

About Study 211

Study 211 is a Phase II, open-label, single-arm study evaluating the efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer who had received an anthracycline, a taxane and capecitabine as prior therapy, and who were refractory to their last chemotherapy regimen, as documented by progression on or within six months of that therapy.

Of 299 patients enrolled in the study, 291 were treated with eribulin mesylate. The median age of those patients was 56 years (range: 26-80 years). Eribulin mesylate was administered at a dose of 1.4mg/m2 as a 2- to 5-minute intravenous infusion on Days 1 and 8 of a 21-day cycle. Patients receiv
'/>"/>

SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
2. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
3. Results of VYVANSE(TM) (lisdexamfetamine dimesylate) Pivotal Trial in Adult ADHD Presented at Major Scientific Meeting
4. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
5. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
6. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
7. Milnacipran Demonstrated Significant Improvement in Pain and the Core Symptoms of Fibromyalgia Syndrome, Data Show
8. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
9. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
10. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
11. Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 Research and Markets has ... Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018" ... and Development Trend Forecast of Pharmaceutical Equipment Market in ... China,s pharmaceutical equipment industry in the ... landscape, and business performance of domestic major enterprises, as ...
(Date:8/29/2014)... , Aug. 29, 2014  Unilife Corporation ("Unilife" ... announced today that it intends to release its financial ... ended June 30, 2014 after market trading ends on ... scheduled a conference call for 4:30 p.m. U.S. EDT ... at 6:30 a.m. AEST), to review the Company,s financial results, ...
(Date:8/29/2014)... Aug. 29, 2014  Pacific Medical Data Solutions is ... website design . The main website, along with the ... company,s new services and content relevant to the medical ... streamlined design, viewers can now better understand how PMDS ... practices and create a more visible platform about medical ...
Breaking Medicine Technology:Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2PMDS Announces New Website 2
... Preliminary results,were released today from a late-stage clinical ... study did not meet its primary or secondary,endpoints of ... people with moderate disease., The findings are initial ... known as the EXPLORER study. Rituxan is approved by ...
... 29 Medarex, Inc.,(Nasdaq: MEDX ) announced today ... melanoma, prostate cancer and other cancers, as,well as for ... to be the subject of presentations at the Annual,Meeting ... May,30-June 3, 2008 in Chicago:, Survival, Response, ...
Cached Medicine Technology:Statement From the Lupus Foundation of America Regarding the Release of Top-Line Results From a Study of Rituxan for the Treatment of Lupus 2Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology 2Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology 3Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology 4
(Date:8/31/2014)... An analysis of 32 studies compiled by University ... between lower levels of Vitamin D and a higher ... 2014 issue of American Journal of Public Health, ... D found in blood. , Researchers found that ... 9 nanograms/milliliter (ng/mL) were twice as likely to die ...
(Date:8/31/2014)... MedixSafe has become very popular in the ... narcotics lockers . Electronic Security Specialists has ... worldwide. “We have now shipped multiple orders to Canada ... Manager , MedixSafe is a division of Electronic Security ... company with over 30 years in the security arena. ...
(Date:8/31/2014)... (PRWEB) August 31, 2014 Just in time ... serving up only wild, sustainable Alaska Salmon, award winning ... at the Duke's Green Lake location , Sunday, September ... expect to sample several ethnic salmon BBQ culinary delights. Live ... Salmon recipes from Hawaii, Puerto Rico and Mexico will be ...
(Date:8/31/2014)... Recently, BambooIndustry.com, one of the most popular suppliers of bamboo ... bamboo veneers . Additionally, it has deiced offer autumn ... quality products. The promotion will last from today until September ... top quality veneers are hot in the global market. “We ... veneers. All these items are made according to our latest ...
(Date:8/31/2014)... AZ (PRWEB) August 31, 2014 Stuart ... Mesa, Arizona, prescribes sublingual immunotherapy to help his ... tree nut allergies. Dr. Agren said that it has ... foods and, in many cases, restored peace of mind. ... lead to a host of symptoms, including rashes, digestive ...
Breaking Medicine News(10 mins):Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 2Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 3Health News:NutriGold Highlights New Study on the Importance of Vitamin D to Our Life Span 4Health News:Memphis-based Electronic Security Specialists Now Offers MedixSafe Narcotics Cabinets Internationally 2Health News:Memphis-based Electronic Security Specialists Now Offers MedixSafe Narcotics Cabinets Internationally 3Health News:Seattle Seafood Restaurant Duke's Chowder House on Green Lake Will Celebrate The Long Anticipated Indian Summer With First Annual Sizzling BBQ Salmon Tasting Event. 2Health News:High Quality Bamboo Veneers from Bambooindustry.com Receive International Attention 2Health News:Family Allergy Clinic Announces Q4 2014 Release of Oral Drops for Tree Nut Allergies 2Health News:Family Allergy Clinic Announces Q4 2014 Release of Oral Drops for Tree Nut Allergies 3
... WASHINGTON, May 15 A new report, funded and ... 1,500 drug codes from its,CY 2008 Part D Formulary ... these drugs from their Medicare offerings in 2008,resulting in ... The CMS action was driven in part to remove ...
... Men Employees Hold Large Companies to a Higher Standard with ... Mandatory Healthcare ... women (58%) were more likely than men (47%) to find paying,for healthcare ... likely than men (42%) to have done some retirement,healthcare planning., Gender ...
... identified hundreds of genes involved in the development of cancer ... find the cancer causing mutations. , The study found ... 350 regions in the mouse genome in cancer formation. 50 ... in human cancers while the other regions were novel, adding ...
... to Raise Money for HIV ... Services in Tri-State Area, NEW YORK, May 15 Duane ... donate $50,000 as,a Grand-level sponsor of AIDS Walk New York, which ... programs and,services in the tri-state area. Since 1986, the annual walk ...
... real-world problems ... in radiology, BOSTON, May ... medical image and information management solutions,today announced that its complete suite of ... 2008,Annual Meeting in Seattle, WA, from May 15 to 18. AMICAS will ...
... Vendormate, Inc., the leading provider,of business-credentialing ... from risky vendors, completes its tenure at,Georgia ... ATDC is a,nationally-recognized science and technology incubator ... companies., ATDC provides strategic business advice ...
Cached Medicine News:Health News:Avalere Report Shows Unapproved Prescription Drugs Dropped from CMS Formulary Reference File 2Health News:Avalere Report Shows Unapproved Prescription Drugs Dropped from CMS Formulary Reference File 3Health News:Avalere Report Shows Unapproved Prescription Drugs Dropped from CMS Formulary Reference File 4Health News:Guardian Survey: Employees Are Confused About Their Health Coverage and Have No Plans for Healthcare in Retirement 2Health News:Guardian Survey: Employees Are Confused About Their Health Coverage and Have No Plans for Healthcare in Retirement 3Health News:Guardian Survey: Employees Are Confused About Their Health Coverage and Have No Plans for Healthcare in Retirement 4Health News:Guardian Survey: Employees Are Confused About Their Health Coverage and Have No Plans for Healthcare in Retirement 5Health News:Connecting cancer genes 2Health News:Duane Reade Announces Proud Sponsorship of AIDS Walk New York 2Health News:AMICAS Focuses on the Future of Radiology IT at SIIM 2008 2Health News:AMICAS Focuses on the Future of Radiology IT at SIIM 2008 3Health News:Vendormate Graduates ATDC Technology Incubator Program 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: